Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase III extension of canakinumab in systemic juvenile idiopathic arthritis
NL-OMON38236Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) (2 cohorts), sponsored by Novartis. Primary endpoints: Long-term safety, tolerability, and immunogenicity of canakinumab, Maintenance of adapted pediatric ACR 30 response and 3 more. Started Feb 2010; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NL-OMON38236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38236.